Why Invest in Healthcare and Life Sciences as an Asset Class

What makes healthcare a distinct asset class, not just a sector?

Most sectors sell things people want. Healthcare sells things people need, at the moments they can least afford to go without. That single fact changes the shape of the demand curve, and it is the foundation of the investment case.

Healthcare and life sciences is best understood not as a vertical inside the economy but as a claim on one of its largest and most inelastic spending pools. In the United States, national health expenditure has run at roughly a sixth to a fifth of gross domestic product in recent years, and long-range projections from federal actuaries have generally pointed to that share continuing to rise rather than revert. An asset class defined by need rather than discretionary want behaves differently through a cycle, prices risk differently, and rewards a different kind of investor. Understanding those differences is the whole of the opportunity.

Why is demand for healthcare so durable?

Durability in healthcare comes from three overlapping sources that do not switch off in a recession.

The first is biological. Disease does not wait for a better funding environment. A patient with cancer, heart failure, or an autoimmune condition needs care on the timeline of the disease, not the timeline of the market. Demand is set by biology, and biology is indifferent to sentiment.

The second is structural. Much of healthcare spending is intermediated by government programs and insurers rather than paid at the point of need out of a household’s monthly budget, which decouples utilization from short-term consumer confidence. When people delay a discretionary purchase in a downturn, spending falls quickly. Care that is medically necessary and reimbursed does not compress the same way.

The third is cumulative. Medicine rarely un-invents a standard of care. Each genuine advance, a new therapeutic class, a better diagnostic, a less invasive procedure, tends to become the floor rather than the ceiling, adding to the base of what is expected and paid for. Demand in this asset class ratchets. It builds on itself.

How do demographics underwrite the opportunity?

The clearest tailwind in healthcare is one you can forecast decades out with unusual confidence, because the people who will drive it have already been born.

Populations across the developed world, and increasingly the emerging one, are aging. Older adults consume health resources at a multiple of younger cohorts, and per-person healthcare spending tends to rise steeply with age. As a large generation moves into its highest-utilization decades, the base of demand widens mechanically, independent of any policy choice or market mood.

Aging does not only add patients, it changes the mix of disease toward the chronic, the degenerative, and the multi-condition, precisely the areas where current medicine is least complete and where new science has the most room to create value. Demography is the rare variable in venture that is both enormous and legible. You are not betting on whether the demand arrives. You are choosing where, within a demand curve you can already see, to stand.

What scientific tailwinds are expanding the frontier?

Underwriting a rising tide of demand would matter less if the ability to meet it were flat. It is not. Over the past two decades the cost of the core tools of biology has fallen sharply and their reach has widened, and the effects are compounding.

The genomic layer has moved from a single reference sequence produced over years at extraordinary cost to routine, inexpensive sequencing, turning biology into a data-rich discipline and making whole categories of precision diagnostics and targeted therapies feasible for the first time.

The tools layer, from gene editing to advances in protein engineering, single-cell measurement, and synthetic biology, has widened what is technically addressable, converting diseases once thought intractable into engineering problems with plausible paths.

The computational layer, machine learning applied to molecular structure, imaging, clinical data, and discovery, is beginning to shorten some of the slowest and most expensive steps of the pipeline. The point is not that AI replaces biology. It is that applied intelligence, pointed at the right biological problem with the right data, can compress timelines that used to define the risk. These layers reinforce one another, and the frontier they define is moving faster than the market has fully priced.

How does healthcare hold up in a downturn?

The resilience of healthcare demand is not a claim that healthcare investing is safe. It is a claim that its risks are largely uncorrelated with the ones that dominate a downturn.

When capital tightens, discretionary and cyclical businesses feel it first and most, because their revenue is tied to spending that can be deferred. A therapeutic program’s value, by contrast, is driven by clinical and regulatory milestones that advance on their own clock. A successful readout can create value in a bear market as readily as a bull one, because the value was never a function of the market. It was a function of the biology.

This is what makes the asset class a genuine diversifier rather than a beta play on the broader technology cycle. The sector is not immune to capital markets, funding windows for later-stage biotech do open and close, but the underlying value driver, does the science work, sits largely outside the macro. For a portfolio, that lack of correlation is not a footnote. It is the point.

Why does the earliest stage capture the most value?

If the demand is durable and the science is accelerating, the natural question is where in the value chain an investor is best paid. Sonnerie’s answer is the beginning.

A defining feature of life-sciences value creation is that some of the largest revaluations happen early, when a program crosses from unproven hypothesis to de-risked asset. The move from a promising mechanism to the first credible evidence that it works is where uncertainty collapses fastest, and where price and eventual value are often furthest apart. Capital that arrives after that crossing pays for a resolution it did not fund.

The earliest stage is also where the fewest investors are equipped to underwrite well. Judging a first-in-class idea at the bench requires reading science that has not yet become a deck, assessing a founding scientist, and distinguishing a real mechanistic insight from an elegant story. That is difficult, it does not scale by spreadsheet, and it is exactly why the opportunity persists. The signal is loudest before the noise of a priced round arrives. Sonnerie is built to be in the room at that moment.

What role do university spinouts play?

The frontier of healthcare science does not originate on a product roadmap. It originates in a lab, usually a university lab, years before it is a company.

University spinouts are where some of the deepest, most differentiated science enters the market. The work is peer-reviewed, pressure-tested by the slow adversarial process of academic publication, and often protected by institutional intellectual property before a company exists. What these teams typically lack is not insight but translation, the operating scaffolding, commercial framing, and early capital that turn a breakthrough into a fundable enterprise.

That gap is the specific inefficiency an operator-led, early-stage fund is built to close. Backing spinouts is not a thematic preference for Sonnerie, it is where the rawest signal lives, closest to the source and furthest from the crowd. Standing at the university bench, at the pre-seed and seed stage, is a deliberate choice to underwrite science before the market has agreed on what it is worth.

How does the risk and return shape differ from software?

Healthcare and software reward capital in structurally different ways, and conflating them is one of the more common and expensive mistakes an investor can make.

Software risk is largely commercial and continuous. Will customers adopt, will the model scale, will growth compound. Progress is incremental and observable in metrics, and a company can iterate its way toward the answer. Life-sciences risk is largely technical and closer to binary. The molecule works or it does not, the trial reads out or it does not, and the answer often arrives as a step function rather than a slope.

This produces a different return distribution and demands a different temperament. Outcomes are lumpier, timelines are longer, and a single milestone can revalue a company in either direction. It is why serious life-sciences investing is patient by construction, measured over the long arc a therapeutic program actually needs, often a decade or more from bench to approval, rather than a shorter software cadence, and why diligence is scientific before it is financial. For an allocator, this is a feature, not a defect. It is precisely because the risk is technical rather than macro that the returns are shaped unlike anything else in a venture portfolio.

Do returns and impact actually align here?

Impact and returns are usually presented as a trade, a discount you accept on one to gain the other. In early-stage healthcare, that trade largely disappears.

The mechanism of return in this asset class is a therapy, a diagnostic, or a tool that measurably improves or extends a human life. Value accrues to the investor because value was delivered to a patient and a health system. The financial upside and the human outcome are produced by the same event, a program that works, which is a rarer alignment than most of finance offers.

This is not a reason to be sentimental about the science, and it is not a substitute for discipline. It is a reason the discipline is worth sustaining. Capital directed at genuine unmet need, underwritten rigorously and held patiently, can compound in both dimensions at once. For founders and limited partners weighing where durable, differentiated returns may come from over the next decade, healthcare and life sciences is not merely one option among many. It is the asset class where demand is most certain, the science is moving fastest, and the earliest capital is paid the most to be right. That is the signal Sonnerie exists to hear early.